Parameters of ‘peroxidation — antioxidant defense’ system and platelet–derived growth factor level in endocrine ophthalmopathy in the course of glucocorticoid pulse therapy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

INTRODUCTION: Endocrine ophthalmopathy (EO) is a multifactorial autoimmune disease, with the need of further study of immunological and biochemical pathogenetic factors of this disease.

AIM: To assess the levels of thiobarbituric acid reactive substances (TBARS), total antioxidant activity, and the BB isoform of platelet–derived growth factor (PDGF-BB) in patients with EO in the course of glucocorticoid pulse therapy.

MATERIALS AND METHODS: A total of 30 individuals were examined, from which 2 groups were formed: a control group (n = 15) and a clinical group of patients with an active phase of EO before and after glucocorticoid pulse therapy (n = 15). A comparative clinical and laboratory analysis was conducted that included a comprehensive ophthalmological examination, determination of TBARS level, of the total antioxidant activity and PDGF-BB in blood serum.

RESULTS: TBARS concentration in the EO group before glucocorticoid pulse therapy exceeded values of the control group (р < 0.001) and did not differ from the parameters after treatment (р = 0.683). The total antioxidant activity before treatment was reduced compared to the control (р < 0.001) and also had no significant differences with the parameters after treatment (р = 0.345). The level of PDGF-BB in the active phase of EO before pulse therapy 2.3 times exceeded that of the control group (р < 0.001), 1.5 times decreased with pulse therapy (р < 0.001), but remained 1.6 times (р = 0.008) the control. Statistically significant relationships were found between the content of PDGF-BB and parameters of ‘peroxidation — antioxidant defense’ system (p < 0.001).

CONCLUSION: In patients with EO in the active phase, an imbalance in the ‘peroxidation — antioxidant defense’ system was found in terms of increased production of TBARS. In the course of glucocorticoid pulse therapy, the identified imbalance persisted. In the active phase of the disease, a significant increase in the level of PDGF-BB was detected, with the concentration remaining elevated after treatment. Correlations were established between the parameters of oxidative stress and the level of PDGF-BB. In view of the obtained data, it seems necessary to develop and introduce the alternative treatment methods for EO targeted at trigger points in the pathogenesis of this disease.

Full Text

Restricted Access

About the authors

Elizaveta S. Taskina

Chita State Medical Academy

Author for correspondence.
Email: Taskins@yandex.ru
ORCID iD: 0000-0002-6223-8888
SPIN-code: 5687-2122

MD, Cand. Sci. (Med.)

Russian Federation, Chita

Svetlana V. Kharintseva

Chita State Medical Academy

Email: s.v.19.28@mail.ru
ORCID iD: 0000-0002-8899-5465
SPIN-code: 6788-2110

MD, Dr. Sci. (Med.), Professor

Russian Federation, Chita

Tatyana M. Karavaeva

Chita State Medical Academy

Email: KaTany1@yandex.ru
ORCID iD: 0000-0002-0487-6275
SPIN-code: 5483-1547

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Chita

References

  1. Zheng J, Duan H, You S, et al. Research progress on the patho-genesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes. Front Immunol. 2022;13:952954. doi: 10.3389/fimmu.2022.952954
  2. Mishra S, Maurya VK, Kumar S, et al. Clinical management and therapeutic strategies for the Thyroid-Associated ophthalmopathy: current and future perspectives. Curr Eye Res. 2020;45(11):1325–41. doi: 10.1080/02713683.2020.1776331
  3. Hoang TD, Stocker DJ, Chou EL, et al. Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022;51(2):287–304. doi: 10.1016/j.ecl.2021.12.004
  4. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–67. doi: 10.1530/eje-21-0479
  5. Längericht J, Krämer I, Kahaly GJ. Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab. 2020;11:2042018820958335. doi: 10.1177/2042018820958335
  6. Tregubova NV. The role of lipid peroxidation in inflammation. Newsletter of North-Caucasus Federal University. 2013;(2):101–5. (In Russ).
  7. Ma C, Li H, Lu S, et al. Thyroid-associated ophthalmopathy: the role of oxidative stress. Front Endocrinol (Lausanne). 2024;15:1400869. doi: 10.3389/fendo.2024.1400869
  8. Hou T–Y, Wu S–B, Kau H–C, et al. The Role of Oxidative Stress and Therapeutic Potential of Antioxidants in Graves' Ophthalmopathy. Biomedicines. 2021;9(12):1871. doi: 10.3390/biomedicines9121871
  9. Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88. doi: 10.1016/j.mam.2017.11.007
  10. Van Steensel L, Paridaens D, van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2012;97(3):E400–8. doi: 10.1210/jc.2011-2697
  11. Andrae J, Gallini R, Betsholtz C. Role of platelet–derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–312. doi: 10.1101/gad.1653708
  12. Virakul S, Dalm VASH, Paridaens D, et al. Platelet–derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts. Invest Ophthalmol Vis Sci. 2015;56(9):5457–64. doi: 10.1167/iovs.15-17001
  13. Lee J–Y, Yun M, Paik J–S, et al. PDGF-BB Enhances the Proliferation of Cells in Human Orbital Fibroblasts by Suppressing PDCD4 Expression Via Up-Regulation of microRNA-21. Invest Ophthalmol Vis Sci. 2016;57(3):908–13. doi: 10.1167/iovs.15-18157
  14. Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001;37(5):970–80. doi: 10.1016/s0272-6386(05)80013-7
  15. Alekseyev VV, Alipov AN, Andreyev VA, et al.; Karpishchenko AI, editor. Meditsinskiye laboratornyye tekhnologii. Rukovodstvo po klinicheskoy i laboratornoy diagnostike. 3rd ed. Moscow: GEOTAR-Media; 2013. Vol. 2. (In Russ).
  16. Promyslov MSh, Demchuk ML. A modified method of determination of the total serum antioxidant activity. Vopr Med Khim. 1990;36(4):90–2. (In Russ).
  17. Taskina ES, Charinzeva SV. The role of interleukins 17, 23 and antibodies to the thyroid-stimulating hormone receptor in the pathogenesis of endocrine ophthalmopathy. Clinical and Experimental Thyroidology. 2018;14(2):72–80. (In Russ). doi: 10.14341/ket9703
  18. Castaldo M, Zollo C, Esposito G, et al. NOX2-Dependent Reactive Oxygen Species Regulate Formyl-Peptide Receptor 1-Mediated TrkA Transactivation in SH-SY5Y Cells. Oxid Med Cell Longev. 2019;2019: 2051235. doi: 10.1155/2019/2051235
  19. Fan X, Wu J, Yang H, et al. Paeoniflorin blocks the proliferation of vascular smooth muscle cells induced by platelet–derived growth factor BB through ROS mediated ERK1/2 and p38 signaling pathways. Mol Med Rep. 2018;17(1):1676–82. doi: 10.3892/mmr.2017.8093
  20. Galgoczi E, Katko M, Papp FR, et al. Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves' Orbitopathy. Molecules. 2022;28(1):15. doi: 10.3390/molecules28010015

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Correlation relationship between the level of TBARS and PDGF-BB in the group of patients with endocrine ophthalmopathyy. Notes: TBARS — thiobarbituric acid reactive substance, PDGF-BB — platelet–derived growth factor-BB.

Download (75KB)
Indexing metadata
3. Fig. 2. Correlation relationship between the level of TAA and PDGF-BB in the group of patients with endocrine ophthalmopathy. Notes: TAA — total antioxidant activity; PDGF-BB — platelet–derived growth factor-BB.

Download (70KB)
Indexing metadata

Copyright (c) 2025 Eco-Vector


Media Registry Entry of the Federal Service for Supervision of Communications, Information Technology and Mass Communications (Roskomnadzor) PI No. FS77-76803 dated September 24, 2019.